在严重和不严重的COVID-19后四个月的循环calprotectin水平
N Abu Hussein1,2, C Machahua1,2, S C Ruchti1,3
1Department of Pulmonary Medicine, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland.
BMC infectious diseases
|October 3, 2023
概括
在COVID-19后在重症监护室 (ICU) 住院的患者中,高的calprotectin水平与肺功能减弱相关. 这表明炎症可能会导致严重疾病后持续的呼吸功能障碍.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 传染性疾病 传染性疾病
背景情况:
- 炎症标记物calprotectin在严重的COVID-19中升高.
- 一些患者在COVID-19后恢复后观察到持续的呼吸系统损伤,包括肺部扩散能力降低.
- 这种长期肺功能障碍的原因尚不清楚.
研究的目的:
- 调查COVID-19后患者血清calprotectin水平和持续性肺功能障碍之间的相关性.
- 探索calprotectin,肺功能和之前的重症监护病房 (ICU) 住院之间的关联.
主要方法:
- 在两个瑞士大学医院,在COVID-19感染四个月后,在192名患者 (ICU后和非ICU) 中测量了血清calprotectin水平.
- 评估了临床参数,包括肺功能测试 (DLCO和FVC).
- 使用多变量线性回归分析来评估关联.
主要成果:
- 与非ICU患者相比,ICU后的患者在感染后四个月内表现出明显更高的calprotectin水平.
- 卡尔蛋白蛋白水平与肺部对一氧化碳的扩散能力 (DLCO) 和强迫生命能力 (FVC) 有负相关.
- 与非ICU患者相比,ICU后的患者的DLCO值较低.
结论:
- 血清calprotectin的升高与COVID-19后四个月患者的肺功能降低有关,特别是那些之前入住了ICU的患者.
- 根据calprotectin的指示,炎症可能在COVID-19后观察到的持续性肺功能障碍中发挥作用.
- 需要进一步的研究来阐明炎症和COVID-19的长期呼吸系统后果之间的关系.
相关概念视频
01:28Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:29Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...